keyword
MENU ▼
Read by QxMD icon Read
search

Hiv-1

keyword
https://www.readbyqxmd.com/read/29220699/hiv-1-tat-protein-induces-dna-damage-in-human-peripheral-blood-b-lymphocytes-via-mitochondrial-ros-production
#1
Rawan El-Amine, Diego Germini, Vlada V Zakharova, Tatyana Tsfasman, Eugene V Sheval, Ruy A N Louzada, Corinne Dupuy, Chrystèle Bilhou-Nabera, Aline Hamade, Fadia Najjar, Eric Oksenhendler, Marс Lipinski, Boris V Chernyak, Yegor S Vassetzky
Human immunodeficiency virus (HIV) infection is associated with B-cell malignancies in patients though HIV-1 is not able to infect B-cells. The rate of B-cell lymphomas in HIV-infected individuals remains high even under the combined antiretroviral therapy (cART) that reconstitutes the immune function. Thus, the contribution of HIV-1 to B-cell oncogenesis remains enigmatic. HIV-1 induces oxidative stress and DNA damage in infected cells via multiple mechanisms, including viral Tat protein. We have detected elevated levels of reactive oxygen species (ROS) and DNA damage in B-cells of HIV-infected individuals...
December 5, 2017: Redox Biology
https://www.readbyqxmd.com/read/29220350/deep-sequencing-of-near-full-length-hiv-1-genomes-from-plasma-identifies-circulating-subtype-c-and-infrequent-occurrence-of-ac-recombinant-form-in-southern-india
#2
Shuba Varshini Alampalli, Michael M Thomson, Raghavan Sampathkumar, Karthi Sivaraman, Anto Jesuraj U K J, Chirag Dhar, George D Souza, Neil Berry, Annapurna Vyakarnam
India has the third largest number of HIV-1-infected individuals accounting for approximately 2.1 million people, with a predominance of circulating subtype C strains and a low prevalence of subtype A and A1C and BC recombinant forms, identified over the past two decades. Recovery of near full-length HIV-1 genomes from a plasma source coupled with advances in next generation sequencing (NGS) technologies and development of universal methods for amplifying whole genomes of HIV-1 circulating in a target geography or population provides the opportunity for a detailed analysis of HIV-1 strain identification, evolution and dynamics...
2017: PloS One
https://www.readbyqxmd.com/read/29218117/basis-and-statistical-design-of-the-passive-hiv-1-antibody-mediated-prevention-amp-test-of-concept-efficacy-trials
#3
Peter B Gilbert, Michal Juraska, Allan C deCamp, Shelly Karuna, Srilatha Edupuganti, Nyaradzo Mgodi, Deborah J Donnell, Carter Bentley, Nirupama Sista, Philip Andrew, Abby Isaacs, Yunda Huang, Lily Zhang, Edmund Capparelli, Nidhi Kochar, Jing Wang, Susan H Eshleman, Kenneth H Mayer, Craig A Magaret, John Hural, James G Kublin, Glenda Gray, David C Montefiori, Margarita M Gomez, David N Burns, Julie McElrath, Julie Ledgerwood, Barney S Graham, John R Mascola, Myron Cohen, Lawrence Corey
Background: Anti-HIV-1 broadly neutralizing antibodies (bnAbs) have been developed as potential agents for prevention of HIV-1 infection. The HIV Vaccine Trials Network and the HIV Prevention Trials Network are conducting the Antibody Mediated Prevention (AMP) trials to assess whether, and how, intravenous infusion of the anti-CD4 binding site bnAb, VRC01, prevents HIV-1 infection. These are the first test-of-concept studies to assess HIV-1 bnAb prevention efficacy in humans. Methods: The AMP trials are two parallel phase 2b HIV-1 prevention efficacy trials conducted in two cohorts: 2700 HIV-uninfected men and transgender persons who have sex with men in the United States, Peru, Brazil, and Switzerland; and 1500 HIV-uninfected sexually active women in seven countries in sub-Saharan Africa...
January 2017: Statistical Communications in Infectious Diseases
https://www.readbyqxmd.com/read/29216346/darunavir-ritonavir-monotherapy-at-a-low-dose-600-100%C3%A2-mg-day-in-hiv-1-infected-individuals-with-suppressed-hiv-viraemia
#4
S Seang, L Schneider, T Nguyen, M P Lê, C Soulie, R Calin, F Caby, M-A Valantin, R Tubiana, L Assoumou, A-G Marcelin, G Peytavin, C Katlama
Background: Darunavir/ritonavir is a potent PI with a high genetic barrier and pharmacological robustness favourably investigated as monotherapy. Whether darunavir could be dose reduced in the context of monotherapy deserves investigation. Methods: Patients with HIV suppressed viraemia (plasma viral load <50 copies/mL for 12 months) under ART who had switched to darunavir/ritonavir monotherapy at 600/100 mg/day between 2013 and 2015 were included in this observational 48 week single-centre study...
December 5, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29216247/the-glycoprotein-of-vesicular-stomatitis-virus-promotes-release-of-virus-like-particles-from-tetherin-positive-cells
#5
Constantin Brinkmann, Markus Hoffmann, Anastasia Lübke, Inga Nehlmeier, Annika Krämer-Kühl, Michael Winkler, Stefan Pöhlmann
Vesicular stomatitis virus (VSV) release from infected cells is inhibited by the interferon (IFN)-inducible antiviral host cell factor tetherin (BST-2, CD317). However, several viruses encode tetherin antagonists and it is at present unknown whether residual VSV spread in tetherin-positive cells is also promoted by a virus-encoded tetherin antagonist. Here, we show that the viral glycoprotein (VSV-G) antagonizes tetherin in transfected cells, although with reduced efficiency as compared to the HIV-1 Vpu protein...
2017: PloS One
https://www.readbyqxmd.com/read/29214845/high-hiv-1-rna-among-newly-diagnosed-people-in-botswana
#6
Vladimir Novitsky, Melanie Prague, Sikhulile Moyo, Tendani Gaolathe, Mompati Mmalane, Etienne Kadima Yankinda, Unoda Chakalisa, Refeletswe Lebelonyane, Nealia Khan, Kathleen M Powis, Erik Widenfelt, Simani Gaseitsiwe, Scott L Dryden-Peterson, Molly Pretorius Holme, Victor De Gruttola, Pam Bachanas, Joseph Makhema, Shahin Lockman, M Essex
OBJECTIVE: HIV-1 RNA level is strongly associated with HIV transmission risk. We sought to determine whether HIV-1 RNA level was associated with prior knowledge of HIV status among treatment-naïve HIV-infected individuals in Botswana, a country with high rates of antiretroviral treatment (ART) coverage. This information may be helpful in targeting HIV diagnosis and treatment efforts in similar high-HIV-prevalence settings. DESIGN: Population-based survey. METHODS: HIV-infected individuals were identified during a household survey performed in 30 communities across Botswana...
December 7, 2017: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/29214737/efficacy-safety-and-patient-reported-outcomes-of-ledipasvir-sofosbuvir-in-ns3-4a-protease-inhibitor-experienced-individuals-with-hepatitis-c-virus-genotype-1-and-hiv-coinfection-with-and-without-cirrhosis-anrs-hc31-softrih-study
#7
E Rosenthal, C Fougerou-Leurent, A Renault, M P Carrieri, F Marcellin, R Garraffo, E Teicher, H Aumaitre, K Lacombe, F Bailly, E Billaud, S Chevaliez, S Dominguez, M A Valantin, J Reynes, A Naqvi, L Cotte, S Metivier, V Leroy, M Dupon, T Allegre, P De Truchis, V Jeantils, J Chas, D Salmon-Ceron, P Morlat, D Neau, P Perré, L Piroth, S Pol, M Bourlière, G P Pageaux, L Alric, D Zucman, P M Girard, I Poizot-Martin, Y Yazdanpanah, F Raffi, E Le Pabic, C Tual, A Pailhé, I Amri, E Bellissant, J M Molina
OBJECTIVES: Studies evaluating the efficacy and safety of the fixed-dose combination ledipasvir (LDV)/sofosbuvir (SOF) in patients coinfected with HIV-1 and hepatitis C virus (HCV) have mainly included treatment-naïve patients without cirrhosis. We aimed to evaluate the efficacy and safety of this combination in treatment-experienced patients with and without cirrhosis. METHODS: We conducted a multicentre, open-label, double-arm, nonrandomized study in patients coinfected with HIV-1 and HCV genotype 1 with and without cirrhosis, who had good viral suppression on their antiretroviral regimens...
December 7, 2017: HIV Medicine
https://www.readbyqxmd.com/read/29214223/novel-elvitegravir-nanoformulation-approach-to-suppress-the-viral-load-in-hiv-infected-macrophages
#8
Yuqing Gong, Pallabita Chowdhury, Narasimha M Midde, Mohammad A Rahman, Murali M Yallapu, Santosh Kumar
Purpose: Monocytes serve as sanctuary sites for HIV-1 from which virus is difficult to be eliminated. Therefore, an effective viral suppression in monocytes is critical for effective antiretroviral therapy (ART). This study focuses on a new strategy using nanoformulation to optimize the efficacy of ART drugs in HIV-infected monocytes. Methods: Poly(lactic-co-glycolic acid) (PLGA)-based elvitegravir nanoparticles (PLGA-EVG) were prepared by nano-precipitation technique...
December 2017: Biochemistry and Biophysics Reports
https://www.readbyqxmd.com/read/29213273/targeting-trim5%C3%AE-in-hiv-cure-strategies-for-the-crispr-cas9-era
#9
Daryl Anne Victoria Weatherley, Michael Terence Boswell, Sarah L Rowland-Jones
In the past decade, studies of innate immune activity against HIV-1 and other retroviruses have revealed a powerful array of host factors that can attack the virus at various stages of its life cycle in human and primate cells, raising the prospect that these antiviral factors could be manipulated in immunotherapeutic strategies for HIV infection. This has not proved straightforward: while HIV accessory genes encode proteins that subvert or destroy many of these restriction factors, others, such as human TRIM5α show limited potency against HIV-1...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29213206/hiv-transmission-clusters-among-injecting-drug-users-in-romania
#10
Aura Temereanca, Cristiana Oprea, Joel O Wertheim, Irina Ianache, Emanoil Ceausu, Costin Cernescu, Sanjay R Mehta, Simona Ruta
Injection drug use is increasingly an important route of HIV transmission in Romania (from 1.5% of the newly diagnosed cases prior to 2010 to 31% in 2013). In this study we investigated the viral characteristics and relationships in newly HIV infected persons who inject drugs in Bucharest, Romania. Results: HIV-1 pol sequencing, followed by phylogenetic and clustering analysis was performed on blood from 37 injecting drug users (IDUs) newly diagnosed with HIV infection. While HIV subtype F1, the dominant strain in Romania since 1990, remains prevalent, new subtypes were found including G, B, B/G and B/F recombinants...
January 2017: Romanian Biotechnological Letters
https://www.readbyqxmd.com/read/29212942/factors-leading-to-the-loss-of-natural-elite-control-of-hiv-1-infection
#11
María Pernas, Laura Tarancón-Diez, Esther Rodríguez-Gallego, Josep Gómez, Julia G Prado, Concepción Casado, Beatriz Dominguez-Molina, Isabel Olivares, Maite Coiras, Agathe León, Carmen Rodriguez, Jose Miguel Benito, Norma Rallón, Montserrat Plana, Onofre Martinez-Madrid, Marta Dapena, Jose Antonio Iribarren, Jorge Del Romero, Felipe García, José Alcamí, M Ángeles Muñoz-Fernández, Francisco Vidal, Manuel Leal, Cecilio Lopez-Galindez, Ezequiel Ruiz-Mateos
HIV-1 elite controllers (EC) maintain undetectable viral load (VL) in the absence of antiretroviral treatment. However, these subjects have heterogeneous clinical outcomes including a proportion loosing HIV-1 control over time. In this work we compared, in a longitudinal design, transient EC, analyzed before and after the loss of virological control, versus persistent EC. The aim was to identify factors leading to the loss of natural virological control of HIV-1-infection with a longitudinal retrospective study design...
December 6, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29212940/hiv-1-envelope-glycoprotein-trafficking-through-the-endosomal-recycling-compartment-is-required-for-particle-incorporation
#12
Junghwa Kirschman, Mingli Qi, Lingmei Ding, Jason Hammonds, Krista Dienger-Stambaugh, Jaang-Jiun Wang, Lynne A Lapierre, James R Goldenring, Paul Spearman
The HIV-1 envelope glycoprotein (Env) encodes specific trafficking signals within its long cytoplasmic tail (CT) that regulate incorporation into HIV-1 particles. Rab11-Family Interacting Protein 1C (FIP1C) and Rab14 are host trafficking factors required for Env particle incorporation, suggesting that Env undergoes sorting from the endosomal recycling compartment (ERC) to the site of particle assembly on the plasma membrane. We disrupted outward sorting from the ERC by expressing a C-terminal fragment of FIP1C (FIP1C560-649) and examined the consequences on Env trafficking and incorporation into particles...
December 6, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29212937/experimental-adaptive-evolution-of-sivcpz-to-pandemic-hiv-1-using-a-humanized-mouse-model
#13
Kei Sato, Naoko Misawa, Junko S Takeuchi, Tomoko Kobayashi, Taisuke Izumi, Hirofumi Aso, Shumpei Nagaoka, Keisuke Yamamoto, Izumi Kimura, Yoriyuki Konno, Yusuke Nakano, Yoshio Koyanagi
HIV-1, the causative agent of AIDS, is originated from SIVcpz, the chimpanzee precursor of the human virus, approximately 100 years ago. This indicates that HIV-1 has emerged through the cross-species transmission of SIVcpz from chimpanzees to humans. However, it remains unclear how SIVcpz has evolved into pandemic HIV-1 in humans. To address this question, we inoculated three SIVcpz (MB897, EK505, and MT145), four pandemic HIV-1 (NL4-3, NLCSFV3, JRCSF and AD8) and 2 non-pandemic HIV-1 (YBF30 and DJO0131) strains...
December 6, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29212213/the-bromodomain-and-extraterminal-domain-inhibitor-bromosporine-synergistically-reactivates-latent-hiv-1-in-latently-infected-cells
#14
Hanyu Pan, Panpan Lu, Yinzhong Shen, Yanan Wang, Zhengtao Jiang, Xinyi Yang, Yangcheng Zhong, He Yang, Inam Ulla Khan, Muya Zhou, Bokang Li, Ziyu Zhang, Jianqing Xu, Hongzhou Lu, Huanzhang Zhu
The long-lived latent HIV-1 reservoir is the major barrier for complete cure of Acquired Immune Deficiency Syndrome (AIDS). Here we report that a novel bromodomain and extraterminal domain (BET) inhibitor bromosporine which can broadly target BETs, is able to potently reactivate HIV-1 replication in different latency models alone and more powerful when combined with prostratin or TNF-α. Furthermore, the treatment with bromosporine induced HIV-1 full-length transcripts in resting CD4+ T cells from infected individuals with suppressive antiretroviral therapy (ART) ex vivo, with no obvious cytotoxicity or global activation of T cell...
November 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/29212076/resistance-associated-mutations-and-polymorphisms-among-integrase-inhibitor-na%C3%A3-ve-hiv-1-patients-in-kuwait
#15
Wassim Chehadeh, Osama Albaksami, Sonia Elezebeth John, Widad Al-Nakib
OBJECTIVES: Resistance-associated mutations (RAMs) in the integrase of different HIV-1 subtypes were investigated in a cohort of patients never exposed to integrase strand transfer inhibitors (INSTIs). METHODS: The viral RNA was extracted from plasma samples of 53 INSTI-naïve patients, and the integrase genetic region was sequenced and analyzed for subtype assignment and drug resistance. RESULTS: The median viral load at sampling was 5.28 × 104 RNA copies/mL...
December 7, 2017: Intervirology
https://www.readbyqxmd.com/read/29212041/soluble-prefusion-closed-ds-sosip-664-env-trimers-of-diverse-hiv-1-strains
#16
M Gordon Joyce, Ivelin S Georgiev, Yongping Yang, Aliaksandr Druz, Hui Geng, Gwo-Yu Chuang, Young Do Kwon, Marie Pancera, Reda Rawi, Mallika Sastry, Guillaume B E Stewart-Jones, Angela Zheng, Tongqing Zhou, Misook Choe, Joseph G Van Galen, Rita E Chen, Christopher R Lees, Sandeep Narpala, Michael Chambers, Yaroslav Tsybovsky, Ulrich Baxa, Adrian B McDermott, John R Mascola, Peter D Kwong
The elicitation of autologous neutralizing responses by immunization with HIV-1 envelope (Env) trimers conformationally stabilized in a prefusion closed state has generated considerable interest in the HIV-1 vaccine field. However, soluble prefusion closed Env trimers have been produced from only a handful of HIV-1 strains, limiting their utility as vaccine antigens and B cell probes. Here, we report the engineering from 81 HIV-1 strains of soluble, fully cleaved, prefusion Env trimers with appropriate antigenicity...
December 5, 2017: Cell Reports
https://www.readbyqxmd.com/read/29211835/massive-iatrogenic-outbreak-of-human-immunodeficiency-virus-type-1-in-rural-cambodia-2014-2015
#17
François Rouet, Janin Nouhin, Du-Ping Zheng, Benjamin Roche, Allison Black, Sophearot Prak, Marie Leoz, Catherine Gaudy-Graffin, Laurent Ferradini, Chandara Mom, Sovatha Mam, Charlotte Gautier, Gérard Lesage, Sreymom Ken, Kerya Phon, Alexandra Kerleguer, Chunfu Yang, William Killam, Masami Fujita, Chhivun Mean, Didier Fontenille, Francis Barin, Jean-Christophe Plantier, Trevor Bedford, Artur Ramos, Vonthanak Saphonn
Background: In 2014-2015, 242 individuals aged 2-89 were newly HIV-1 diagnosed in Roka, a rural commune in Cambodia. A case-control study attributed the outbreak to unsafe injections. We aimed to reconstruct the likely transmission history of the outbreak. Methods: We assessed in 209 (86.4%) HIV-infected cases the presence of hepatitis C and B viruses (HCV, HBV). We identified recent infections using antibody (Ab) avidity testing for HIV and HCV, and HBcIgM Ab for HBV...
December 4, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29211834/long-term-therapeutic-impact-of-the-timing-of-art-in-patients-diagnosed-with-primary-hiv-1-infection
#18
Sophie Novelli, Camille Lécuroux, Véronique Avettand-Fenoel, Rémonie Seng, Asma Essat, Philippe Morlat, Jean-Paul Viard, Christine Rouzioux, Laurence Meyer, Cécile Goujard
Background: We aimed to determine the consequences of delayed HIV-1 infection diagnosis by comparing long-term outcomes depending on the time of combination antiretroviral therapy (cART) initiation in patients diagnosed during primary HIV infection (PHI). Methods: We selected patients from the ANRS PRIMO cohort, treated for ≥36 months, with sustained HIV-RNA< 50 copies/mL: 77 treated within one month following PHI diagnosis (immediate ART) and 73 treated >12 months after infection (deferred ART)...
December 2, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29210661/impact-of-different-antiretroviral-strategies-on-total-hiv-dna-level-in-virologically-suppressed-hiv-1-infected-patients
#19
Isabella Bon, Leonardo Calza, Giuseppina Musumeci, Serena Longo, Alessia Bertoldi, Vanessa D'Urbano, Davide Gibellini, Eleonora Magistrelli, Pier Luigi Viale, Maria Carla Re
Background Total HIV-DNA load in peripheral blood cell (PBMCs) reflects the global viral reservoir that seems to be not affect by antiretroviral treatment. However, some studies reported a different permeability of different drugs in cellular compartments. Objective To investigate the relation between the amount of total HIV-1 DNA and different treatment strategies. Method Total HIV-1 DNA was quantified by real time PCR in PBMCs collected from 161 patients with long-term undetectable HIV-RNA receiving different therapy schedules (3-drug regimens or 2-drug regimen containing Raltegravir as integrase inhibitor)...
December 6, 2017: Current HIV Research
https://www.readbyqxmd.com/read/29210660/host-factors-predictors-in-long-term-nonprogressors-hiv-1-infected-with-distinct-viral-clades
#20
J S Santos, S M Almeida, G F Silveira, J Bordignon, S Lm Teixeira, Acm Lima, S M Raboni
BACKGROUND: HIV-1+ long-term non-progressors (LTNPs) maintain natural control of viral infection. This study sought to identify and characterize HIV- LTNPs series case, regarding the presence of possible host factors that may be associated with this status. METHODS: We evaluated the plasma levels of IP-10/IL-8 chemokines, HLA-B alleles, and IL28B rs12979860 polymorphism in 24 LTNPs who presented with infection by different clades of HIV-1. RESULTS: IL-8 chemokine was significantly higher in progressors than in LTNPs, but there was no difference between the LTNP subgroups...
December 6, 2017: Current HIV Research
keyword
keyword
15325
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"